Press Releases

Date	Title and Summary	View
Dec 22, 2017	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the
Nov 06, 2017	Agile Therapeutics Reports Third Quarter 2017 Financial Results Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three and
Oct 31, 2017	Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017 Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes
Oct 16, 2017	Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017 Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational
Oct 10, 2017	Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy Company Also Announces Four New Patents Granted for its Novel Transdermal Contraceptive Dosing Regimens
Oct 02, 2017	Agile Therapeutics to Host First Analyst Day on October 10, 2017 PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City. Members of Agile's executive team will review clinical data and
Sep 28, 2017	Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch (AG200-15) has been selected for a
Sep 14, 2017	Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Presentation Scheduled on Tuesday, September 26th, 2017 at 11:30 AM ET
Sep 07, 2017	Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE study of its investigational low-dose combined hormonal contraceptive patch (AG200-15) has been
Aug 22, 2017	Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Presentation Scheduled on Tuesday, September 12th, 2017 at 9:10 AM ET